Condition : Coxarthrosis Interventions : Device: porous coated Trilogy®; Device: Trilogy Calcicoat® Sponsors : Northern Orthopaedic Division, Denmark; Northern Orthopaedic Division, Denmark Completed...

Condition : Coxarthrosis Interventions : Device: porous coated Trilogy®; Device: Trilogy Calcicoat® Sponsor : Northern Orthopaedic Division, Denmark Completed - verified August 2011

Condition : Gout Interventions : Drug: Placebo; Drug: Febuxostat; Drug: Febuxostat; Drug: Febuxostat Sponsor : Takeda Global Research & Development Center, Inc. Completed - verified July 2011

Condition : Rheumatoid Arthritis Intervention : Biological: Certolizumab pegol (CDP870) Sponsor : UCB, Inc. Active, not recruiting - verified February 2011

Condition : Coxarthrosis Interventions : Device: porous coated Trilogy®; Device: Trilogy Calcicoat® Sponsor : Northern Orthopaedic Division, Denmark Completed - verified August 2011

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

An open ended study in which patients who completed the double-blind study (CDP870-050) are given Certolizumab pegol and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed t...

Condition : Rheumatoid Arthritis Intervention : Drug: Certolizumab pegol (CDP870) Sponsors : UCB, Inc.; UCB, Inc. Completed - verified July 2010

Conditions : Anemia; Rheumatoid Arthritis Intervention : Drug: Epoetin alfa Sponsor : Ortho Biotech Products, L.P. Withdrawn - verified July 2011

Condition : Rheumatoid Arthritis Interventions : Drug: tocilizumab [RoActemra/Actemra]; Drug: Methotrexate Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Completed - verified September 2013